Levetiracetam Treatment of Tardive Dyskinesia

This study has been completed.

Sponsors and Collaborators:	Yale University UCB
Information provided by:	Yale University
ClinicalTrials.gov Identifier:	NCT00291213

Purpose

This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.

Condition	Intervention	Phase
Tardive Dyskinesia	Drug: levetiracetam Drug: placebo	Phase III

Drug Information available for: Levetiracetam

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Further study details as provided by Yale University:

Primary Outcome Measures:

Eligibility

Criteria

Inclusion Criteria: meet Glazer Morgenstern criteria for TD -

Exclusion Criteria: none

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00291213

Locations

United States, Connecticut
Connecticut Mental Health Center
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

Yale University

UCB

Investigators

Principal Investigator:

Scott W Woods, MD

Yale School of Medicine

More Information

Publications indexed to this study:

Study ID Numbers:	YaleHIC26585
Study First Received:	February 10, 2006
Last Updated:	February 10, 2006
ClinicalTrials.gov Identifier:	NCT00291213
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Signs and Symptoms
Movement Disorders
Neurologic Manifestations
Central Nervous System Diseases

Etiracetam
Dyskinesias
Tardive dyskinesia
Oral facial dyskinesia

Additional relevant MeSH terms:

Nootropic Agents
Therapeutic Uses
Nervous System Diseases

Central Nervous System Agents
Pharmacologic Actions
Anticonvulsants

ClinicalTrials.gov processed this record on January 16, 2009